BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Porta C, Pedrazzoli P, Paglino C. Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab. Immunotherapy 2011;3:487-90. [PMID: 21463189 DOI: 10.2217/imt.11.19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
Number Citing Articles
1 Kamińska K, Czarnecka AM, Escudier B, Lian F, Szczylik C. Interleukin-6 as an emerging regulator of renal cell cancer. Urol Oncol 2015;33:476-85. [PMID: 26296264 DOI: 10.1016/j.urolonc.2015.07.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
2 Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, Giunta V, De Amici M. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013;84:115-22. [PMID: 23154434 DOI: 10.1159/000342099] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.8] [Reference Citation Analysis]
3 Porta C, Bracarda S. 3rd Pavia international symposium on advanced kidney cancer. Expert Opin Pharmacother 2012;13:445-53. [PMID: 22263875 DOI: 10.1517/14656566.2012.651461] [Reference Citation Analysis]